Curis (NASDAQ:CRIS) Posts Earnings Results

Curis (NASDAQ:CRIS) announced its quarterly earnings data on Tuesday. The biotechnology company reported ($2.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.94) by ($0.11), RTT News reports. Curis had a negative net margin of 473.04% and a negative return on equity of 169.22%. The company had revenue of $2.09 million for the quarter, compared to analysts’ expectations of $2.31 million. During the same period last year, the firm earned ($2.40) earnings per share.

Curis Price Performance

CRIS stock traded down $0.20 during mid-day trading on Wednesday, reaching $16.00. 3,087 shares of the company’s stock were exchanged, compared to its average volume of 32,570. The company has a market cap of $94.30 million, a price-to-earnings ratio of -1.81 and a beta of 3.59. Curis has a 12-month low of $3.80 and a 12-month high of $19.60. The stock’s 50 day moving average is $12.94 and its 200 day moving average is $11.00.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and set a $26.00 price target on shares of Curis in a research report on Wednesday.

Curis Company Profile

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.